Compare Ascendis Pharma A/S (ASND) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Jones Lang LaSalle Inc — how do they compare? Ascendis Pharma A/S trades at $255.5 (market cap $16.67B), while Jones Lang LaSalle Inc trades at $365.99 (market cap $16.72B). The key difference: Ascendis Pharma A/S and Jones Lang LaSalle Inc are close in size by market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| ASND | JLL | |
|---|---|---|
Market Cap | $16.67B | $16.72B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $373.24 |
52-Week Low | $189.74 | $280.16 |
Enterprise Value | $17.04B | $19.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
